{"title":"Aflibercept – a novel agent for VEGF-driven macular disease","authors":"George Morphis MD, FEBO","doi":"10.1002/fps.95","DOIUrl":null,"url":null,"abstract":"<p>Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 2","pages":"5-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.95","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.95","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aflibercept is a novel vascular endothelial growth factor (VEGF) inhibitor that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD). In this Drug profile Mr George Morphis presents the clinical data relating to its efficacy and adverse events, and discusses its potential place in therapy. Copyright © 2012 John Wiley & Sons, Ltd.
afliberept -一种用于vegf驱动的黄斑疾病的新型药物
afliberept是一种新型血管内皮生长因子(VEGF)抑制剂，最近被美国食品和药物管理局(FDA)批准用于治疗湿性年龄相关性黄斑变性(AMD)。在这篇药物简介中，George Morphis先生介绍了有关其疗效和不良事件的临床数据，并讨论了其在治疗中的潜在地位。版权所有©2012 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
